Development and optimization of a meloxicam/-cyclodextrin complex for orally disintegrating tablet using statistical analysis

被引:22
作者
Ainurofiq, Ahmad [1 ]
Choiri, Syaiful [1 ,2 ]
机构
[1] Sebelas Maret Univ, Dept Pharm, Surakarta, Indonesia
[2] Gadjah Mada Univ, Fac Pharm, Yogyakarta, Indonesia
关键词
Meloxicam; beta-cyclodextrin complexes; QbD; ODT; crushing strength; Primellose; Primojel; BETA-CYCLODEXTRIN; PHYSICOCHEMICAL PROPERTIES; FORMULATION; DESIGN; DISSOLUTION; QUALITY; SYSTEMS; TASTE; OSTEOARTHRITIS; DICLOFENAC;
D O I
10.1080/10837450.2016.1264418
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this research was to develop an inclusion complex of meloxicam (MEL)/-cyclodextrin (-CD) incorporated into an orally disintegrating tablet (ODT), using statistical analysis to optimize the ODT formulation based on a quality by design (QbD) approach. MEL/-CD complexation was performed by kneading, co-precipitation and spray drying methods under different molar ratios. Fourier transform infrared spectroscopy, X-ray diffraction and thermal analysis were utilized to evaluate the complexes. A central composite design (=2) was applied to optimize and assess the influence of Primojel, Primellose and crushing strength (CS) as independent variables on tablet friability, disintegration behavior, wicking properties and drug release. The spray drying method induced formation of an amorphous complex and enhanced solubility and drug release of MEL. Furthermore, a QbD-based statistical analysis was successfully utilized to optimize the ODT formulation. Primojel, Primellose and CS showed unique main effects and interactions at different levels. CS was the dominant factor, affecting friability, disintegration behavior and drug release, while wicking properties were affected by Primojel and its interaction with Primellose. Therefore, according to the overlay plot, CS was dominant factor in determining the optimum region based on a QbD approach.
引用
收藏
页码:464 / 475
页数:12
相关论文
共 42 条
[1]   Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam [J].
Ambrus, R. ;
Kocbek, P. ;
Kristl, J. ;
Sibanc, R. ;
Rajko, R. ;
Szabo-Revesz, P. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 381 (02) :153-159
[2]  
[Anonymous], 2008, GUID IND OR DIS TABL
[3]  
[Anonymous], 2005, AAPS PHARM SCI TECH, DOI DOI 10.1208/PT060479
[4]  
[Anonymous], 2011, PHARM EUR EUR PHARM
[5]   Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets [J].
Badawy, Sherif I. F. ;
Narang, Ajit S. ;
LaMarche, Keirnan R. ;
Subramanian, Ganeshkumar A. ;
Varia, Sailesh A. ;
Lin, Judy ;
Stevens, Tim ;
Shah, Pankaj A. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 105 (01) :168-181
[6]   Formulation and evaluation of rapidly disintegrating fenoverine tablets: Effect of superdisintegrants [J].
Battu, Sunil Kumar ;
Repka, Michael A. ;
Majumdar, Soumyajit ;
Rao, Madhusudan Y. .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2007, 33 (11) :1225-1232
[7]   Cyclodextrins as pharmaccutical solubilizers [J].
Brewster, Marcus E. ;
Loftsson, Thorsteinn .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) :645-666
[8]   Cycloxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation [J].
Chen, Y-F ;
Jobanputra, P. ;
Barton, P. ;
Bryan, S. ;
Fry-Smith, A. ;
Harris, G. ;
Taylor, R. S. .
HEALTH TECHNOLOGY ASSESSMENT, 2008, 12 (11) :1-+
[9]   OPTIMIZATION AND ACESSING THE INFLUENCE OF XANTHAN GUM, EFFERVESCENT COMPONENTS AND HARDNESS ON FLOATATION BEHAVIOR AND DRUG RELEASE OF GASTROFLOATING CAPTOPRIL TABLET [J].
Choiri, Syaiful ;
Sulaiman, T. N. Saifullah ;
Kuncahyo, Ilham .
INDONESIAN JOURNAL OF PHARMACY, 2014, 25 (04) :255-264
[10]   Studies on the complexation of diclofenac sodium with β-cyclodextrin: Influence of method of preparation [J].
Das, Subhraseema ;
Subuddhi, Usharani .
JOURNAL OF MOLECULAR STRUCTURE, 2015, 1099 :482-489